The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perspectives on under-representation of minority patients (pts) in clinical trials.
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Eisai; EMD Serono; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Wells Fargo; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Luis E. Raez
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Lee S. Schwartzberg
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Genentech; Helsinn Therapeutics; Lilly; Myriad Genetics; Napo Pharmaceuticals; Odonate Therapeutics; Pfizer; Spectrum Pharmaceuticals
Speakers' Bureau - Coherus Biosciences; Merck; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); Pfizer (Inst)
 
Randall F. Holcombe
Consulting or Advisory Role - Merck
Other Relationship - Merck
 
Lewis R. Roberts
Consulting or Advisory Role - Bayer (Inst); Biocompatibles (Inst); Exact Sciences (Inst); GRAIL (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); TAVEC (Inst)
Speakers' Bureau - Bayer
Research Funding - ARIAD (Inst); BTG (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Glycotest (Inst); RedHill Biopharma (Inst); Wako Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics. Royalties (Inst); Five Prime Therapeutics. Royalties.; US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Gregory A. Vidal
Employment - West Cancer Center and Research Institute
Stock and Other Ownership Interests - Oncodisc
Consulting or Advisory Role - AstraZeneca; Biotheranostics; Daiichi Sankyo; Immunomedics; Lilly; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Vector Oncology
Speakers' Bureau - Lilly
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celcuity; Halozyme; Immunomedics; Lilly; Merck; Pfizer; Puma Biotechnology; Roche/Genentech; Tesaro
Travel, Accommodations, Expenses - Lilly
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
May Thet Cho
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Eisai; Exelixis; Genentech/Roche; Ipsen; QED Therapeutics; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); incyte (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune